A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma

Abstract

Background We conducted a phase II study of the combination of pembrolizumab with capecitabine and oxaliplatin (CAPOX) in patients with advanced biliary tract carcinoma (BTC) to assess response rate and clinical efficacy. Exploratory objectives included correlative studies of immune marker expression, tumor evolution, and immune infiltration in response to treatment. Patients and Methods Adult patients with histologically confirmed BTC were enrolled and received oxaliplatin and pembrolizumab on day 1 of cycles 1-6. Capecitabine was administered orally twice daily as intermittent treatment, with the first dose on day 1 and the last dose on day 14 of cycles 1-6. Starting on cycle 7, pembrolizumab monotherapy was continued until disease progression. The primary endpoint was progression-free survival (PFS). Secondary endpoints were safety, tolerability, feasibility, and response rate. Immunohistochemistry (IHC) for PD-L1 and immune infiltrates was analyzed in paired tumor biopsies, as well as bulk transcriptome and exome profiling for five patients and single-cell RNA sequencing for one partial responder. Results Eleven patients enrolled, three of whom had received no prior systemic therapy. Treatment was well tolerated, and the most common treatment-related grade 3 or 4 adverse events were lymphocytopenia, anemia, and decreased platelet count. Three patients (27.3%) achieved a partial response, and six (54%) had stable disease. The disease control rate was 81.8%. The median PFS was 4.1 months with a 6-month PFS rate of 45.5%. Molecular profiling suggests qualitative differences in immune infiltration and clonal evolution based on response. Conclusion Capecitabine and oxaliplatin in combination with pembrolizumab is tolerable and a potentially effective treatment for refractory advanced BTC. This study highlights a design framework for the precise characterization of individual BTC tumors. Trial Registration This study was registered in ClinicalTrials.gov (NCT03111732).

PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: A retrospective analysis of a case series

“…In a phase II study of pembrolizumab plus capecitabine and oxaliplatin (CapOx) for 11 patients with BTC, 8 of patients had received one or more systemic platinum-based chemotherapies. Three patients with GBC were enrolled, 2 of whom were evaluated for SD and 1 for PR ( 34 ).…”

Exploiting RIG-I-like receptor pathway for cancer immunotherapy

“…Since radio-chemotherapy-induced DNA damage may activate RLRs signaling and induce an immune response, the combination of radio-chemotherapy with immune checkpoint inhibitors has been evaluated in clinical trials [ 318 , 319 ]. The randomized PACIFIC study demonstrates that treatment of stage III NSCLC patients, who do not have disease progression after platinum-based chemoradiotherapy, with anti-PD-L1 antibody durvalumab improves the overall survival [ 271 ].…”

Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies

“…Durvalumab is an IgG1 κ monoclonal antibody, which acts as a PD-L1 blocker, can bind to PD-L1 on tumor cells, and block its interaction with PD-1 of T cells and antigen-presenting cells, thereby relieving PD-1/PD-L1-mediated immunouppression, promoting T cell proliferation, and strengthening the immune killing effect on tumors. A controlled trial involving 685 cases showed that Durvalumab combined with GEMCIS significantly prolonged OS compared with GEMCIS 119 , and similar regimens were Camrelizumab combined with GEMOX and Pmbrolizumab combined with CAPOX 120 , 121 . The above studies showed that the combination of PD-L1 blocker and chemotherapeutic drugs had good efficacy in patients with advanced CCA.…”